Roche's Genentech Reports Positive Phase 3 Data for Autoimmune Disorder Treatment

Dow Jones04-22

By Kelly Cloonan

Roche Group's Genentech said its Enspryng drug lowered the risk of relapse for patients with a type of autoimmune disorder in a Phase 3 study, meeting the study's primary endpoint.

Genentech said Tuesday the treatment reduced the risk of a new relapse by 68% compared to placebo in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

MOGAD is a rare autoimmune disease of the central nervous system that affects the optic nerves, and can also affect the brain and spinal cord. It can lead to severe symptoms such as loss of vision, pain, fatigue, numbness and cognitive dysfunction. Relapsing can lead to multiple, unpredictable attacks of worsening neurological symptoms, the company said.

The data show the drug has the potential to become the first approved treatment for MOGAD, the company said. The company plans to submit the Phase 3 data to regulatory authorities globally.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

April 21, 2026 12:23 ET (16:23 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629056902?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-22 00:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629056902","market":"hk","top_or_hot":-1,"title":"Roche's Genentech Reports Positive Phase 3 Data for Autoimmune Disorder Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Roche Group's Genentech said its Enspryng drug lowered the risk of relapse for patients with a type of autoimmune disorder in a Phase 3 study, meeting the study's primary endpoint. \n</p>\n<p>\n  Genentech said Tuesday the treatment reduced the risk of a new relapse by 68% compared to placebo in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). \n</p>\n<p>\n  MOGAD is a rare autoimmune disease of the central nervous system that affects the optic nerves, and can also affect the brain and spinal cord. It can lead to severe symptoms such as loss of vision, pain, fatigue, numbness and cognitive dysfunction. Relapsing can lead to multiple, unpredictable attacks of worsening neurological symptoms, the company said. \n</p>\n<p>\n  The data show the drug has the potential to become the first approved treatment for MOGAD, the company said. The company plans to submit the Phase 3 data to regulatory authorities globally. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2026 12:23 ET (16:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's Genentech Reports Positive Phase 3 Data for Autoimmune Disorder Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's Genentech Reports Positive Phase 3 Data for Autoimmune Disorder Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-22 00:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Roche Group's Genentech said its Enspryng drug lowered the risk of relapse for patients with a type of autoimmune disorder in a Phase 3 study, meeting the study's primary endpoint. \n</p>\n<p>\n  Genentech said Tuesday the treatment reduced the risk of a new relapse by 68% compared to placebo in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). \n</p>\n<p>\n  MOGAD is a rare autoimmune disease of the central nervous system that affects the optic nerves, and can also affect the brain and spinal cord. It can lead to severe symptoms such as loss of vision, pain, fatigue, numbness and cognitive dysfunction. Relapsing can lead to multiple, unpredictable attacks of worsening neurological symptoms, the company said. \n</p>\n<p>\n  The data show the drug has the potential to become the first approved treatment for MOGAD, the company said. The company plans to submit the Phase 3 data to regulatory authorities globally. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2026 12:23 ET (16:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RHHBY","symbol_name":"罗氏控股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629056902","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629056902","pubTimestamp":1776788580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Roche Group's Genentech said its Enspryng drug lowered the risk of relapse for patients with a type of autoimmune disorder in a Phase 3 study, meeting the study's primary endpoint.Genentech said Tuesday the treatment reduced the risk of a new relapse by 68% compared to placebo in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease .MOGAD is a rare autoimmune disease of the central nervous system that affects the optic nerves, and can also affect the brain and spinal cord. It can lead to severe symptoms such as loss of vision, pain, fatigue, numbness and cognitive dysfunction. Relapsing can lead to multiple, unpredictable attacks of worsening neurological symptoms, the company said.The data show the drug has the potential to become the first approved treatment for MOGAD, the company said. The company plans to submit the Phase 3 data to regulatory authorities globally.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RHHBY":"罗氏控股","03165":"华夏欧优股对冲","BK4007":"制药"},"translate_title":"罗氏旗下基因泰克报告自身免疫性疾病治疗3期积极数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":0.9,"03165":0.6},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Roche Group's Genentech said its Enspryng drug lowered the risk of relapse for patients with a type of autoimmune disorder in a Phase 3 study, meeting the study's primary endpoint. \n\n\n  Genentech said Tuesday the treatment reduced the risk of a new relapse by 68% compared to placebo in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). \n\n\n  MOGAD is a rare autoimmune disease of the central nervous system that affects the optic nerves, and can also affect the brain and spinal cord. It can lead to severe symptoms such as loss of vision, pain, fatigue, numbness and cognitive dysfunction. Relapsing can lead to multiple, unpredictable attacks of worsening neurological symptoms, the company said. \n\n\n  The data show the drug has the potential to become the first approved treatment for MOGAD, the company said. The company plans to submit the Phase 3 data to regulatory authorities globally. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2026 12:23 ET (16:23 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629056902","isCrawlerRequest":true}